J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes
Chief scientific officer Paul Stoffels will retire at the end of the year at the same time CEO Alex Gorsky will hand over the top leadership role to Joaquin Duato; no successor has been named.
You may also be interested in...
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
J&J announced strong data for its single-shot vaccine, with even stronger booster shot data to boot. Also Gilead posted strong results for outpatient use of Veklury, but it faces stiff competition, while Clover announced new data and Pfizer/BioNTech sold another 500 million vaccine doses for donation.
Another vaccine failure shows that HIV’s ability to “attack, hijack and evade” the human immune system is still outwitting researchers, but J&J will continue with Phase III study of a related vaccine.